Lies Dekeyzer

Company: Confo Therapeutics

Job title: Principal Scientist

Seminars:

Confo Therapeutics’ Technology as a Superior Platform for Fragment-Based Drug Discovery on Difficult to Drug GPCRs 4:30 pm

What is the most optimum workflow for performing fragment-based drug discovery to identify selective and ligand efficient small molecules? Is there utility in the ultra-large scale screening of drug-like compounds or should we be more selective?Read more

day: Conference Day One